Washington, United States:
- Dr. Badrul Chowdhury Appointed Chief Life Sciences Officer
- Dr. Matthew Holman Appointed Vice President, U.S. Scientific Engagement and Regulatory Strategy
Philip Morris International Inc. (PMI) (NYSE: PM) introduced at the moment that it has appointed two former United States Food and Drug Administration (U.S. FDA) officers to key positions to speed up its science-based transformation.
Dr. Badrul Chowdhury is appointed PMI’s Chief Life Sciences Officer, Smoke-Free Products, succeeding Jorge Insuasty, who will full his transfer into the not too long ago created place of President, Vectura Fertin Pharma. After a brief transition interval, Badrul will be a part of PMI’s Senior Management Team in January 2023, reporting to Jacek Olczak, Chief Executive Officer.
“I am delighted to welcome Badrul to PMI and look forward to working closely with him as he leads our talented team of scientific experts,” stated Jacek Olczak. “He is an accomplished scientist and regulatory strategist, with decades of leadership experience, both in industry and as a regulator within the U.S. FDA’s Pulmonary Division. His wealth of knowledge and experience will be critical to help achieve our ambition of a smoke-free future. I also extend my sincere thanks to Jorge Insuasty for his contributions to the function as he moves to oversee Vectura Fertin Pharma full-time.”
Dr. Chowdhury joins PMI from a U.S.-based biotech firm creating inhalation merchandise for uncommon respiratory ailments, the place he was Chief Medical Officer. Prior to that, he was AstraZeneca’s Senior Vice President and Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late-Stage Development in Biopharmaceuticals R&D. Before becoming a member of the pharmaceutical trade, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. FDA for nearly 21 years, from 1997 to 2018, offering scientific and regulatory oversight of therapies for lung, autoimmune, and inflammatory ailments. Dr. Chowdhury is a medical physician and holds a PhD in immunology.
“Joining the PMI team is an exciting new adventure,” stated Dr. Chowdhury. “The investment the company has already made in delivering high-quality science to support its transformation and smoke-free vision is unprecedented. I am thrilled to have the chance to help move the company forward faster and to truly seize the public health opportunity that well-regulated smoke-free products present. I look forward to working with the Senior Management Team and the entire Life Sciences function to accelerate progress.”
Dr. Matthew (“Matt”) Holman is appointed as PMI’s Vice President of U.S. Scientific Engagement and Regulatory Strategy, reporting to Deepak Mishra, President of PMI Americas.
“We are delighted that Matt will be joining PMI to further accelerate our journey toward a smoke-free future, particularly here in the United States,” stated Deepak Mishra. “As we transform, we recognize the importance of bringing together diverse perspectives, including those of regulatory bodies and the scientific community. Matt’s solid scientific and stakeholder knowledge, combined with his passion for tobacco harm reduction, will be invaluable.”
Dr. Holman joins PMI from the U.S. FDA, the place he served for greater than 20 years, most not too long ago as Director of the Office of Science at the Center for Tobacco Products (CTP). At CTP, Holman was instrumental in constructing the FDA’s advertising and marketing utility assessment applications. He served as CTP’s chief scientist, enjoying a big function in guiding coverage choices, creating rulemaking and steering paperwork, and overseeing a sturdy regulatory science analysis program for tobacco merchandise. Previously, Holman labored at the FDA’s CDER on over-the-counter drug merchandise, together with as Deputy Director of the Division of Nonprescription Regulation Development. He acquired his PhD in biochemistry from the University of Maryland at College Park.
“Having spent more than two decades working to improve public health as a regulator, I am delighted to join forces with PMI, a company that is firmly committed to the goal of accelerating the end of smoking,” stated Dr. Holman. “PMI is leading the industry in a major transformation that can ultimately provide an unprecedented breakthrough for public health. I’m excited to make this move and join PMI on its smoke-free journey.”
The appointment of these seasoned scientific and regulatory specialists enhances the current hiring of Keagan Lenihan, who joined PMI in May 2022 as Vice President of Government Affairs and Public Policy, and Head of its D.C. workplace. Lenihan spent twenty years working in authorities, company, and public coverage, together with as Associate Commissioner for External Affairs and Strategic Initiatives and then Chief of Staff at the U.S. FDA.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a number one worldwide tobacco firm working to ship a smoke-free future and evolving its portfolio for the long run to embody merchandise outdoors of the tobacco and nicotine sector. The firm’s present product portfolio primarily consists of cigarettes and smoke-free merchandise, together with heat-not-burn, vapor, and oral nicotine merchandise, that are bought in markets outdoors the U.S. Since 2008, PMI has invested greater than USD 9 billion to develop, scientifically substantiate, and commercialize modern smoke-free merchandise for adults who would in any other case proceed to smoke, with the objective of utterly ending the sale of cigarettes. This contains the constructing of world-class scientific evaluation capabilities, notably in the areas of pre-clinical techniques toxicology, scientific and behavioral analysis, in addition to post-market research. The U.S. Food and Drug Administration (FDA) has approved the advertising and marketing of variations of PMI’s IQOS Platform 1 gadgets and consumables as Modified Risk Tobacco Products (MRTPs), discovering that publicity modification orders for these merchandise are applicable to promote the public well being. As of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free merchandise had been out there on the market in 70 markets, and PMI estimates that roughly 13.2 million adults round the world had already switched to IQOS and stopped smoking. With a robust basis and vital experience in life sciences, in February 2021 PMI introduced its ambition to broaden into wellness and healthcare areas and ship modern merchandise and options that purpose to deal with unmet client and affected person wants. For extra data, please go to www.pmi.com and www.pmiscience.com.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220914005023/en/
